دورية أكاديمية

Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table

التفاصيل البيبلوغرافية
العنوان: Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table
المؤلفون: Cosentino, Francesco, Verma, Subodh, Ambery, Philip, Treppendahl, Marianne Bach, van Eickels, Martin, Anker, Stefan D, Cecchini, Michele, Fioretto, Paola, Groop, Per-Henrik, Hess, David, Khunti, Kamlesh, Lam, Carolyn S P, Richard-Lordereau, Isabelle, Lund, Lars H, McGreavy, Paul, Newsome, Philip N, Sattar, Naveed, Solomon, Scott, Weidinger, Franz, Zannad, Faiez, Zeiher, Andreas
المساهمون: Cosentino, Francesco, Verma, Subodh, Ambery, Philip, Treppendahl, Marianne Bach, van Eickels, Martin, Anker, Stefan D, Cecchini, Michele, Fioretto, Paola, Groop, Per-Henrik, Hess, David, Khunti, Kamlesh, Lam, Carolyn S P, Richard-Lordereau, Isabelle, Lund, Lars H, Mcgreavy, Paul, Newsome, Philip N, Sattar, Naveed, Solomon, Scott, Weidinger, Franz, Zannad, Faiez, Zeiher, Andreas
بيانات النشر: OXFORD UNIV PRESS
سنة النشر: 2023
المجموعة: Padua Research Archive (IRIS - Università degli Studi di Padova)
مصطلحات موضوعية: Atherosclerotic cardiovascular disease, Bariatric surgery, COVID-19, Cardiometabolic risk factor, Chronic kidney disease, Chronic liver disease, Glucagon-like peptide-1 receptor agonist, Obesity, Sodium glucose cotransporter-2 inhibitor, Type 2 diabetes mellitus
الوصف: Metabolic comorbidities are common in patients with cardiorenal disease; they can cause atherosclerotic cardiovascular disease (ASCVD), speed progression, and adversely affect prognosis. Common comorbidities are Type 2 diabetes mellitus (T2DM), obesity/overweight, chronic kidney disease (CKD), and chronic liver disease. The cardiovascular system, kidneys, and liver are linked to many of the same risk factors (e.g. dyslipidaemia, hypertension, tobacco use, diabetes, and central/truncal obesity), and shared metabolic and functional abnormalities lead to damage throughout these organs via overlapping pathophysiological pathways. The COVID-19 pandemic has further complicated the management of cardiometabolic diseases. Obesity, T2DM, CKD, and liver disease are associated with increased risk of poor outcomes of COVID-19 infection, and conversely, COVID-19 can lead to worsening of pre-existing ASCVD. The high rates of these comorbidities highlight the need to improve recognition and treatment of ASCVD in patients with obesity, insulin resistance or T2DM, chronic liver diseases, and CKD and equally, to improve recognition and treatment of these diseases in patients with ASCVD. Strategies to prevent and manage cardiometabolic diseases include lifestyle modification, pharmacotherapy, and surgery. There is a need for more programmes at the societal level to encourage a healthy diet and physical activity. Many pharmacotherapies offer mechanism-based approaches that can target multiple pathophysiological pathways across diseases. These include sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, selective mineralocorticoid receptor antagonists, and combined glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist. Non-surgical and surgical weight loss strategies can improve cardiometabolic disorders in individuals living with obesity. New biomarkers under investigation may help in the early identification of individuals at risk and reveal new treatment targets.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37448181; info:eu-repo/semantics/altIdentifier/wos/WOS:001027464200001; volume:44; issue:39; firstpage:4141; lastpage:4156; numberofpages:16; journal:EUROPEAN HEART JOURNAL; https://hdl.handle.net/11577/3504527Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85174921095
DOI: 10.1093/eurheartj/ehad445
الإتاحة: https://doi.org/10.1093/eurheartj/ehad445Test
https://hdl.handle.net/11577/3504527Test
رقم الانضمام: edsbas.76258A91
قاعدة البيانات: BASE